The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Phase II Study of Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer or Peritoneal Serous Cancer
Abstract
Purpose: We evaluated the efficacy and safety of bevacizumab in patients with platinum-resistant epithelial ovarian carcinoma (EOC) or peritoneal serous carcinoma (PSC) who had experienced disease progression during, or within 3 months of discontinuing, topotecan or liposomal doxorubicin. Patients and Methods: No more than three prior treatment regimens were allowed. Patients received single-agent bevacizumab 15 mg/kg intravenously every 3 weeks. Response was assessed by computed tomography (CT) scan every 6 weeks using Response Evaluation Criteria in Solid Tumors (RECIST). Results: Of 44 patients treated, 83.7% were primarily platinum resistant, 59.1% had received liposomal doxorubicin, 25% topotecan, 15.9% both agents, and 47.7% had received three prior chemotherapy regimens. A median of five (range, two to 16) bevacizumab doses were administered. Partial responses were observed in seven patients (15.9%). Median progression-free survival was 4.4 months (95% CI, 3.1 to 5.5 months), with a median survival duration of 10.7 months at study termination. Bevacizumab-associated grade 3 to 4 events included hypertension (9.1%), proteinuria (15.9%), bleeding (2.3%), and wound-healing complications (2.3%). The incidence of GI perforation (GIP; 11.4%) was higher than reported in bevacizumab trials of other tumor types. GIP occurred in 23.8% of patients receiving three prior chemotherapy regimens, compared with 0% of patients receiving two prior chemotherapy regimens (P < .01). A trend toward higher risk of GIP was observed for patients with bowel wall thickening or bowel obstruction on CT scan. Arterial thromboembolic events occurred in three patients (6.8%). Three deaths were related to bevacizumab treatment. Conclusion: Bevacizumab has single-agent activity in patients with platinum-resistant EOC or PSC. A higher than expected incidence of GIP was noted in these heavily pretreated patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.1.43 · Cited by 7,439
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Yang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., & Rosenberg, S. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021491 · Cited by 2,697
Cannistra, S. A. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041842 · Cited by 2,129
Self-citationGordon, A. N., Fleagle, J. T., Guthrie, D., Parkin, D. E., Gore, M. E., & Lacave, A. J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.14.3312 · Cited by 1,211
Gordon, M. S., Margolin, K., Talpaz, M., Sledge, G. W., Holmgren, E., Benjamin, R., Stalter, S., Shak, S., & Adelman, D. C. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.3.843 · Cited by 913
Burger, R. A., Sill, M. W., Monk, B. J., Greer, B. E., & Sorosky, J. I. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.5345 · Cited by 882
Self-citationA phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer
COBLEIGH, M. (2003) · Seminars in Oncology · doi:10.1053/j.seminoncol.2003.08.013 · Cited by 488
Tumor angiogenesis in advanced stage ovarian carcinoma.
Hollingsworth, H. C., Kohn, E. C., Steinberg, S. M., Rothenberg, M. L., & Merino, M. J. (1995) · Europe PMC (PubMed Central) · Cited by 386
Vascular endothelial growth factor expression in early stage ovarian carcinoma
Paley, P. J., Staskus, K. A., Gebhard, K., Mohanraj, D., Twiggs, L. B., Carson, L. F., & Ramakrishnan, S. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970701)80:1<98::aid-cncr13>3.0.co;2-a · Cited by 364
Yamamoto, S., Konishi, I., Mandai, M., Kuroda, H., Komatsu, T., Nanbu, K., Sakahara, H., & Mori, T. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.537 · Cited by 356
Giantonio, B. J., Catalano, P. J., Meropol, N. J., O’Dwyer, P. J., Mitchell, E. P., Alberts, S. R., Schwartz, M. A., & Benson, A. B. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.2 · Cited by 344
Byrne, A. T., Ross, L. H., Holash, J., Nakanishi, M., Hu, L., Hofmann, J., Yancopoulos, G. D., & Jaffe, R. B. (2003) · PubMed · Cited by 310
Radiation Therapy and Tamoxifen: Concurrent or Sequential? That Is the Question
Whelan, T., & Levine, M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.955 · Cited by 304
Canil, C. M., Moore, M. J., Winquist, E., Baetz, T., Pollak, M., Chi, K. N., Berry, S., Ernst, D. S., Douglas, L., Brundage, M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.129 · Cited by 210
Abu‐Jawdeh, G. M., Faix, J. D., Niloff, J. M., Tognazzi, K., Manseau, E. J., Dvorak, H. F., & Brown, L. (1996) · PubMed · Cited by 202
Use of CA-125 to Define Progression of Ovarian Cancer in Patients With Persistently Elevated Levels
Rustin, G. J. S., Marples, M., Nelstrop, A. E., Mahmoudi, M., & Meyer, T. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.20.4054 · Cited by 201
Bevacizumab combination therapy in recurrent, platinum‐refractory, epithelial ovarian carcinoma
Wright, J. D., Hagemann, A. R., Rader, J. S., et al. (2006) · Cancer · doi:10.1002/cncr.21969 · Cited by 128
E2100: A Phase III Trial of Paclitaxel Versus Paclitaxel/Bevacizumab for Metastatic Breast Cancer
Miller, K. D. (2003) · Clinical Breast Cancer · doi:10.3816/cbc.2003.n.007 · Cited by 118
Skillings, J. R., Johnson, D. H., Miller, K. D., Kabbinavar, F. F., Bergsland, E. K., Holmgren, E. B., Holden, S. N., Hurwitz, H. I., & Scappaticci, F. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.3019 · Cited by 95
Cannistra, S. A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.5.1158 · Cited by 61
Self-citationFriberg, G. R., Kasza, K., Vokes, E. E., & Kindler, H. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.3020 · Cited by 43
Optimal unconditional test in 2×2 multinomial trials
Andrés, M., & Garcı́a, T. (1999) · Computational Statistics & Data Analysis · doi:10.1016/s0167-9473(99)00015-8 · Cited by 16
Cited by
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Burger, R. A., Brady, M. F., Bookman, M. A., Fleming, G. F., Monk, B. J., Huang, H., Mannel, R. S., Homesley, H. D., Fowler, J., Greer, B. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104390 · Cited by 2,404
Self-citationA Phase 3 Trial of Bevacizumab in Ovarian Cancer
Perren, T. J., Swart, A. M., Pfisterer, J., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G., Carey, M. S., Beale, P., Cervantes, A., Kurzeder, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103799 · Cited by 2,172
Jayson, G. C., Kohn, E. C., Kitchener, H. C., & Ledermann, J. A. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62146-7 · Cited by 1,850
Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., Venook, A. P., Al-Hawary, M. M., Arain, M. A., Chen, Y.-J., Ciombor, K. K., Cohen, S., Cooper, H. S., Deming, D., Farkas, L., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0012 · Cited by 1,696
Pujade-Lauraine, E., Hilpert, F., Weber, B., Reuss, A., Poveda, A., Kristensen, G., Sorio, R., Vergote, I., Witteveen, P., Bamias, A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.4489 · Cited by 1,622
Metadata
- Authors
- Cannistra, S. A., Matulonis, U. A., Penson, R. T., Hambleton, J., Dupont, J., Mackey, H., Douglas, J., Burger, R. A., Armstrong, D., Wenham, R., & McGuire, W.
- Venue
- Journal of Clinical Oncology
- Published
- 2007-11-20
- Volume
- 25
- Issue
- 33
- Pages
- 5180-5186
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2096521047
- Cited by
- 759
- References
- 25
- FWCI
- 65.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.